Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19

Overview of attention for article published in Frontiers in Medicine, September 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 16 Mendeley

Summary X

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 34,691 followers.

@VirusesImmunity Why Polyclonal Antibodies (pAbs) hasn't been considered yet? This one was very promising and simple to produce https://t.co/Q8ETjJIJAL

30 Dec 2021

Reply Repost Favourite

4/ $SABS The potential of SAB-185 is massive because: (1) Unlike monoclonal, polyclonal does very well at dealing with variants and mutations. (2) Monoclonal treatments cost ~$2,100/dose whereas polyclonal treatments should cost around ~$35/dose. https:

05 Nov 2021

Reply Repost Favourite

RT @keyaki1117: メモ「Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential…

06 Sep 2021

Reply Repost Favourite

RT @keyaki1117: メモ「Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential…

06 Sep 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.